Benchmark Reiterates “Hold” Rating for VolitionRx (NYSE:VNRX)

Benchmark reaffirmed their hold rating on shares of VolitionRx (NYSE:VNRX) in a research report report published on Friday morning,Benzinga reports.

Separately, StockNews.com started coverage on VolitionRx in a research report on Wednesday, November 20th. They set a “sell” rating for the company.

VolitionRx Trading Down 11.3 %

VolitionRx stock opened at $0.70 on Friday. The firm has a market capitalization of $65.22 million, a price-to-earnings ratio of -1.95 and a beta of 1.10. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23. The firm has a 50 day simple moving average of $0.69 and a 200 day simple moving average of $0.68.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC raised its position in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.